Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill target cells for which they have no intrinsic specificity, a phenomenon we call effector cell retargeting (ECR). These studies used bispecific reagents with one specificity directed to CD3 or Ti on the effector cell and the other directed to a target cell antigen. To avoid the need to create different hybrid hybridomas for each target antigen we have developed a universal means to elicit ECR through the use of an antiglobulin step. We have constructed a bispecific hybrid antibody with dual specificity for CD3 and a rat immunoglobulin light chain allotype. This bispecific antibody could mediate ECR to a range of target cells, each coated with distinct surface-binding rat monoclonal antibodies. A particular advantage of targeting to surface-bound monoclonal antibodies is that all other available effector systems may also attack the same antibody-coated target cell.

Original publication

DOI

10.1073/pnas.85.20.7719

Type

Journal article

Journal

Proc Natl Acad Sci U S A

Publication Date

10/1988

Volume

85

Pages

7719 - 7723

Keywords

Animals, Antibodies, Monoclonal, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Antigens, Differentiation, T-Lymphocyte, Binding, Competitive, Humans, Hybridomas, Immunoglobulin Light Chains, Mice, T-Lymphocytes, Cytotoxic, Thymoma, Tumor Cells, Cultured